Table 1.
General and tumor characteristics of study participants (n = 1268).
| Variables | N (Percentage) |
|---|---|
| Age (years) | 59.9 ± 4.2 * |
| Sex (male) | 665 (52.44%) |
| Weight loss | |
| No WL (0–1.9% of body weight) | 801 (63.17%) |
| Mild WL (2–2.9% in 1-month or 2–5.9% in 6 months) | 208 (16.40%) |
| Moderate WL (3–4.9% in 1-month or 6–9.9% in 6 months) | 117 (9.23%) |
| Severe WL (5–9.9% in 1-month or10–19.9% in 6 months) | 88 (6.94%) |
| Very severe WL (>10% in 1-month or >20% in 6 months) | 54 (4.26%) |
| Tumor location | |
| Stomach | 887 (69.95%) |
| Duodenum | 54 (4.26%) |
| Intestine | 235 (18.53%) |
| Colon | 30 (2.37%) |
| Mesentery | 62 (4.89%) |
| Tumor size (cm) | |
| <5.0 | 383 (30.21%) |
| 5.0~10.0 | 789 (62.22%) |
| >10.0 | 96 (7.57%) |
| Nuclear mitotic figure (50HPF) | |
| <5 | 372 (29.34%) |
| 6~10 | 708 (55.84%) |
| >10 | 188 (14.83%) |
| NIH classification | |
| High risk | 279 (22.00%) |
| Moderate risk | 543 (42.82%) |
| Low risk | 309 (24.37%) |
| Very low risk | 137 (10.80%) |
| Ki-67 percentage | |
| ≤ 10% | 848 (66.88%) |
| >10% | 420 (33.12%) |
| c-kit exons | |
| Positive | 961 (75.79%) |
| Negative | 307 (24.21%) |
| PDGFRA exons | |
| Positive | 319 (25.16%) |
| Negative | 949 (74.84%) |
*
Mean ± SD.